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Abstract
Objective—COMBINE is the largest study of pharmacotherapy for alcoholism in the United States
to date, designed to answer questions about the benefits of combining behavioral and
pharmacological interventions. Trajectory-based analyses of daily drinking data allowed
identification of distinct drinking trajectories in smaller studies and demonstrated significant
naltrexone effects even when primary analyses on summary drinking measures were unsuccessful.
The objective of this study was to replicate and refine trajectory estimation and to assess effects of
naltrexone, acamprosate and therapy on the probabilities of following particular trajectories in
COMBINE. It was hypothesized that different treatments may affect different trajectories of drinking.
Methods—We conducted exploratory analyses of daily indicators of any drinking and heavy
drinking using a trajectory-based approach and assessed trajectory membership probabilities and
odds ratios for treatment effects.
Results—We replicated the trajectories (“abstainer”, “sporadic drinker”, “consistent drinker”)
established previously in smaller studies. However, greater numbers of trajectories better described
the heterogeneity of drinking over time. Naltrexone reduced the chance to follow a “nearly daily”
trajectory and Combined Behavioral Intervention (CBI) reduced the chance to be in an “increasing
to nearly daily” trajectory of any drinking. The combination of naltrexone and CBI increased the
probability of membership in a trajectory in which the frequency of any drinking declined over time.
Trajectory membership was associated with different patterns of treatment compliance.
Conclusion—The trajectory-analyses identified specific patterns of drinking that were
differentially influenced by each treatment and provided support for hypotheses about the
mechanisms by which these treatments work.
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Some of the heterogeneity of clinical findings in studies evaluating the efficacy of
pharmacotherapies and behavioral therapies in the treatment of alcohol dependence can be
attributed to the wide use of standard statistical analytical tools of summary drinking measures
that poorly reflect the distributions, variability, and complexity of drinking data. Novel
statistical analysis tools based on trajectories over time provide a more realistic and complete
picture of treatment effects on drinking behavior. In secondary analyses of data from the VA
naltrexone study (Krystal et al., 2001) and the Women’s naltrexone study (O’Malley et al.,
2007), we successfully used trajectory analyses to examine whether there were distinct
trajectories of drinking during treatment and whether naltrexone modified the chance of
following a specific trajectory (Gueorguieva et al., 2007). The results of these analyses were
remarkably similar across the two studies and revealed three trajectories (“abstainers”,
“sporadic drinkers”, and “consistent drinkers”). Despite negative findings on the primary
summary measures based on more traditional analytic methods, in the trajectory-based
reanalysis we demonstrated that naltrexone significantly decreased the chance of being in the
“consistent drinker” trajectory. In a similar reanalysis using latent growth mixture models of
the Project MATCH data, Witkiewitz et al. (2007) also identified three trajectories of drinking
and were able to detect interactions between baseline self-efficacy and treatment (Cognitive
Behavioral Therapy vs. Motivational Enhancement) for frequent drinkers that had not been
detected in the original analyses. These three studies demonstrate the ability of trajectory-based
approaches based on mixture models to capture heterogeneity in drinking data and to identify
trajectories where treatment effects are more pronounced.
Trajectory analyses have been also applied to large-scale observational studies of
developmental patterns of alcohol use (Muthén and Muthén, 2000ab;Hill et al., 2000; Chassin
et al., 2000; Del Boca et al., 2003;Greenbaum et al. 2004). For example, Muthén and Muthén
(2000ab) have explored the development of heavy drinking and alcohol-related problems from
ages 18 to 37 in a nationally representative sample from the National Longitudinal Study of
Youth. Hill et al. (2000) and Chassin et al. (2000) have assessed developmental trajectories of
adolescent binge drinking. Chung et al. (2004,2005) have analyzed drinking patterns and the
relationship of drinking patterns and symptom occurrence in treated adolescents.
In the current manuscript we perform exploratory trajectory analyses to investigate the effects
of naltrexone, acamprosate and the Combined Behavioral Intervention (CBI) in the COMBINE
Study. The COMBINE Study (Anton et al., 2006) represents the largest study of
pharmacotherapy for alcoholism in the United States. It was designed to answer questions about
the benefits of combining behavioral and pharmacological interventions. Naltrexone, an opiate
antagonist, was studied based on evidence that it reduced the risk of heavy drinking and
increased the percentage of days abstinent in most studies (Kranzler and Van Kirk, 2001;
Pettinati et al., 2006; Srisurapanont and Jarusuraisin, 2005). Acamprosate, thought to reduce
glutamatergic hyperactivity associated with protracted abstinence, was chosen because it had
been demonstrated to maintain abstinence within varied behavioral treatment frameworks
(Mann et al., 2004; Mason et al., 2001, 2005; Soyka et al., 2002). The behavioral interventions
examined included Medical Management (MM) (Pettinati et al., 2004, 2005) and the Combined
Behavioral Intervention (CBI) (Longabaugh et al., 2005; Miller et al., 2004). MM was designed
as a means of enhancing medication compliance and reinforcing of sobriety that could be used
in a primary care or managed care settings by nonspecialists (Fleming et al., 1997). CBI
integrated components from cognitive behavioral, motivational enhancement, and 12-step
facilitation therapies originally developed for and evaluated positively in Project MATCH
(1997ab).
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At the time COMBINE was designed, summary measures derived from timeline reports of
daily drinking were the standard approach to assessing outcomes (Babor et al., 1994; Finney
et al., 2003). In COMBINE, the two primary outcomes were time to the first day of heavy
drinking and percent days abstinent in the 16-week treatment period. The primary findings
were that either naltrexone (+ MM) or CBI (+ placebo naltrexone + MM) improved outcomes
compared to MM + placebo and that there was no additional advantage of combining CBI with
naltrexone over each monotherapy. The fact that there was no advantage of combined treatment
with CBI and naltrexone was unanticipated. In addition, the failure to find an effect of
acamprosate either alone or in combination with CBI or naltrexone was particularly unexpected
given the positive studies of acamprosate (Mann et al., 2004; Mason et al., 2005) and of the
combination of acamprosate and naltrexone (Kiefer et al., 2003; Feeney et al., 2006) conducted
in Europe.
Like other studies, the primary outcome measures used by COMBINE have a number of
potential limitations. For example, time to the first heavy day of drinking does not take
advantage of the daily reports of drinking that occur after the first event. The distribution of
percentage of days abstinent is skewed and subject to ceiling effects. None of these summary
measures allow description of temporal trends of the data and the standard statistical analyses
that are typically applied to these measures poorly reflect the multimodal distribution of
drinking data.
Advances in longitudinal statistical modeling enable the use of daily drinking data. Growth
modeling (Lindsey, 1993; Longford, 1993; Diggle 1994; Raudenbush and Bryk, 2002) assumes
that every individual follows the same type of trajectory over time, while mixture approaches
(Muthén and Muthén, 2001ab; Nagin, 1999; Dolan et al., 2005) allow data-driven identification
of distinct classes of developmental trajectories. Thus, it is possible to identify subgroups of
subjects who show distinct patterns of clinical response within a clinical trial based on the
structure of the data generated by that trial, i.e., subgroups that might not have been
hypothesized a priori by the investigative team.
For heterogeneous populations, the trajectory-based approach appears to be more powerful
than the analysis of traditional summary measures of drinking and time to event models. For
example, trajectories capture information on frequency of drinking, duration of abstinence and
rate of change over time. If we were to fit a model using summary measures of drinking we
would have to analyze three highly correlated such measures to capture all these aspects of
drinking. Although no direct comparison of trajectory models to multiple time-to-event
methods (Wang et al., 2002) has been performed to date, the purposes of these analyses are
different and these procedures should be regarded as complementary rather than competing.
In trajectory models the goal is to identify subgroups of subjects who might be more or less
responsive to interventions while in multiple time-to-event models the goal is to take into
account drinking behavior for the population as a whole beyond the first episode of drinking.
The main objective of the trajectory re-analyses of the drinking data in COMBINE was to
estimate distinct trajectories of any drinking and heavy drinking and to assess the effects of
naltrexone, acamprosate and CBI on these trajectories. We hypothesized that different
treatments may affect different trajectories of drinking. In particular, we predicted that there
would be at least three trajectories of drinking over time, similar to those obtained in the VA
naltrexone study and the women’s naltrexone study (“abstainers”, “sporadic drinkers” and
“consistent drinkers”) on any and heavy drinking. We anticipated that naltrexone would
significantly decrease the chance to belong to a “consistent drinker” trajectory as compared to
“sporadic drinker” and “abstainer” trajectories and we hypothesized that CBI would have a
similar effect. Based on the original COMBINE analyses, we did not anticipate that the
combination of CBI and naltrexone would be more beneficial than either CBI or naltrexone
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alone. We also planned to explore acamprosate effects on the probability to follow particular
trajectories although we did not anticipate observing significant results given that the tests of
acamprosate effects were not significant in the original COMBINE analyses.
Given the larger sample size, we further hypothesized that we would be able to find a larger
number of classes of drinking patterns over time in which the “sporadic drinker” and “consistent
drinker” classes might split into subclasses that might show stronger treatment effects. In
particular, we anticipated that naltrexone might be associated with a trajectory of decreasing
drinking over time. Sinclair (1990) hypothesized that extinction of drinking behavior should
occur over time with naltrexone due to attenuation of alcohol reinforcement, and preclinical
studies have demonstrated that naltrexone progressively reduces the onset and duration of
drinking over multiple sessions (Hyttia & Sinclair, 1993). Consistent with this perspective,
naltrexone increased the number of days to a second episode of drinking following a lapse in
abstinence among alcohol dependent patients (e.g., Anton et al., 1999). At the same time, CBI
teaches new skills for coping with situations that otherwise lead to drinking. The benefit of
CBI may not emerge until later during treatment, however, because CBI requires several
sessions to impart this information (Longabaugh et al., 2005). This benefit could conceivably
involve an improvement over time or maintenance of initial improvement. Clinical trials of
cocaine abusers provide evidence that Cognitive Behavior Therapy, a component of CBI, has
a delayed emergence of efficacy involving maintenance of improvements relative to
comparison treatment conditions in which initial gains deteriorated over time (Carroll et al.,
1994; Carroll et al., 2000).
2. Methods
The COMBINE study enrolled 1,383 abstinent alcohol dependent patients. Eight groups
received medication management (MM) and either placebos, naltrexone, acamprosate, or
naltrexone + acamprosate. Half of these groups also received the CBI. Participants on different
treatments were found to be comparable on seventy-six pretreatment characteristics (Anton et
al., 2006). Analyses of the two primary endpoints, time to the first day of heavy drinking and
percent days abstinent, revealed that either naltrexone or CBI without naltrexone improved
outcomes compared to MM + placebo. A ninth group received CBI alone with no pills in order
to examine placebo effects in secondary analyses.
The “Timeline Follow Back” (TLFB) was used to collect daily drinking data. TLFB is the most
comprehensive self-report measure and has good reliability and internal consistency on
summary drinking measures (Sobell and Sobell, 1992,1995). In this trajectory-based reanalysis
we focused on the daily binary indicator of drinking (1 if any drinks were consumed by the
subject on that day, 0 otherwise) or heavy drinking (1 if 5 or more drinks were consumed by
males and 4 or more drinks were consumed by females on that day, 0 otherwise).
We used the approach of Nagin (1999) and Nagin and Tremblay (2001) to identify distinct
trajectories of drinking patterns during the first 16 weeks of the trial and to estimate how
naltrexone, acamprosate and CBI (alone or in combination) affect the probability of following
a particular trajectory. The models assumed fixed polynomial trends over time within each
trajectory class and modeled the effect of treatment (naltrexone, acamprosate, CBI and their
interactions) on trajectory membership via a generalized logistic regression model with the
number of outcome categories equal to the number of trajectory classes. Thus, we estimated
how the odds of being in a trajectory compared to a reference trajectory varied depending on
treatment.
We fit two sets of models for any and heavy drinking. In the first set of models we fixed the
number of trajectories to three to be able to compare our results to the results from the analyses
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of the VA naltrexone trial and the women’s naltrexone study. The second set of models
involved model selection (number of trajectory classes and degree of the polynomial trends
over time such as linear, quadratic) based on the Schwartz Bayesian criterion (BIC) and on
having at least 5% of subjects in each trajectory class. BIC is a criterion of how well the model
fits the data while keeping model complexity low. Only the final models (i.e. the models that
provided the best fit according to BIC) are presented in the Results section. Percent days
abstinent and percent heavy drinking days in 90 days prior to study entry were included as
covariates for any drinking and heavy drinking respectively.
Classification accuracy was assessed using the entropy measure (Muthén, 2004) with values
close to 1 indicating excellent classification of individuals to trajectory classes. Overall tests
of treatment effects were performed first, followed by adjusted (at 0.01 level) pairwise
comparisons among trajectories. Because we have a priori hypotheses regarding naltrexone
and CBI interaction based on the results of COMBINE (Anton et al., 2006), post-hoc
comparisons were performed even if the overall naltrexone by CBI interaction was significant
at 0.10 rather than at 0.05 level.
In an additional exploratory analysis each subject was assigned to the most likely drinking
trajectory and compliance measures (full compliance with prescribed medication dose and
number of MM sessions attended) was compared across trajectories of any drinking using
nonparametric tests (Kruskal-Wallis for the comparison among all trajectories and Wilcoxon
rank-sum test for pairwise comparisons).
Our modeling strategy allowed the data to guide the choice of the number of trajectories that
best fit the data and to determine the shape of each trajectory over time. It also allowed the use
of all available data on each subject and estimation of the proportion of the population whose
treatment response corresponds most closely to each trajectory group. For the analysis we used
a customized SAS procedure (PROC TRAJ) developed by Jones et al. (2001). Test statistics
for overall treatment effects, odds ratios and associated confidence intervals were calculated
in PROC IML. An adjusted confidence level of 99% was used for post-hoc testing in the models
with more than three trajectories. Since 94% of the subjects (treatment group range, 92%-96%)
provided complete within treatment drinking data (Anton et al., 2006), we do not believe that
our results may be materially biased due to missing data.
3. Results
3.1. Replication of drinking trajectories
Figure 1 and Figure 2 plot the estimated trajectories for any and heavy drinking respectively
when the number of trajectories was restricted to three. The models with third-degree
polynomials fit better than the models with second-degree polynomials and are presented here.
The three trajectory patterns over time are similar to the trajectories estimated for the VA
naltrexone trial and the Women’s study and are interpreted as “abstainers” (48.2% of the
sample), “sporadic drinkers” (35.5%) and “consistent drinkers” (16.3%) for any drinking and
“abstainers from heavy drinking” (59.9%), “sporadic heavy drinkers” (29.5%) and “consistent
heavy drinkers” (10.5%) for heavy drinking. In understanding these labels, the “abstainers”
trajectory label does not mean that total abstinence occurred across the entire study period, but
rather that the chance for drinking to occur on a particular day was close to 0. Entropies of the
two models are excellent (0.97 and 0.98 respectively) thus, most subjects were clearly assigned
to a particular trajectory.
Tests for overall treatment effects (naltrexone, acamprosate, CBI and their interactions) did
not reveal any significant effects for any drinking (all p-values > 0.15) while for heavy drinking
the naltrexone by CBI interaction was significant at the 0.10 level (p=0.08). Post-hoc tests for
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heavy drinking (Table 1) revealed that for subjects not receiving CBI, naltrexone compared to
no naltrexone increased the chance for being in the “abstainers from heavy drinking” trajectory
compared to the “consistent heavy drinkers” and “sporadic heavy drinkers” trajectories
(OR=1.86, 95% CI: (1.10, 3.16) and OR=1.48, 95% CI: (1.02, 2.14) respectively). For subjects
not receiving naltrexone, CBI compared to no CBI increased the chance for being in the
“abstainers from heavy drinking” trajectory compared to the “consistent heavy drinkers”
trajectory (OR=1.81, 95% CI: (1.07, 3.06)). Subjects on the combination of naltrexone and
CBI compared to subjects receiving neither naltrexone nor CBI were significantly more likely
to be “abstainers from heavy drinking” than “consistent heavy drinkers” (OR=2.04, 95% CI:
(1.18, 3.53)). There were no acamprosate effects either alone or in combination.
Estimated membership probabilities in each trajectory by treatment (averaged over
acamprosate) are shown in Figure 3 (for any drinking) and Figure 4 (for heavy drinking). The
differences in trajectory membership probabilities were not statistically significant for any
drinking (Figure 3). Figure 4 shows that each treatment alone (i.e., naltrexone, CBI) and the
combination lowers the chance to be in the “consistent heavy drinkers” trajectory but the
combination is not better than either treatment alone. Furthermore, the monotherapies appear
to lower the chance for membership in the “sporadic heavy drinkers” trajectory slightly, while
the combination does not have this effect.
3.2. Any drinking outcome – increasing the number of trajectories
In the first analyses, we restricted the number of trajectories to three to be able to replicate
prior results. However, according to Schwartz-Bayesian information criterion we need more
trajectories to describe the data adequately. According to our model selection algorithm
described in the Methods section, we selected the model with six trajectory classes as the best
fitting one for any drinking. Entropy of this model was excellent (0.95).
Figure 5 plots the estimated trajectories for any drinking with six trajectories. From least severe
to most severe, we interpret these trajectories as “abstainers” (trajectory T1, 37% of the
sample), “infrequent drinkers” (trajectory T2, 24.4%), “frequent to infrequent
drinkers” (trajectory T3, 12.2%), “increasing to frequent drinkers” (trajectory T4, 10.9%),
“increasing to nearly daily drinkers” (trajectory T5, 8%), and “nearly daily drinkers” (trajectory
T6, 7.3%). The first three trajectories (“T1: abstainers”, “T2: infrequent drinkers” and “T3:
frequent to infrequent drinkers”) can be interpreted as “good outcome” trajectories as there is
little or decreasing drinking in them. The last three trajectories (“T4: increasing to frequent
drinkers”, “T5: increasing to nearly daily drinkers” and “T6: nearly daily drinkers”) can be
interpreted as “poor outcome” trajectories in which drinking is frequent and/or increasing.
Estimated membership probabilities in each trajectory by treatment (averaged over
acamprosate) are shown in Figure 6.
Tests for overall treatment effects revealed significant main effect of CBI (p=0.006). Adjusted
post-hoc tests revealed that subjects on CBI compared to those not receiving CBI were less
likely to be in the “T5: increasing to nearly daily drinkers” trajectory than in all other
trajectories. This effect was statistically significant for all trajectories (see first four rows of
Table 2 for odds ratios and 99% confidence intervals) except for “T4: increasing to frequent
drinkers”.
There was also an interaction between CBI and naltrexone (p=0.06). For subjects who received
naltrexone, CBI compared to no CBI increased the chance to be in the “T4: increasing to
frequent”, “T3: frequent to infrequent” and “T6: nearly daily drinkers” trajectories compared
to the “T5: increasing to nearly daily” trajectory. For subjects who did not receive naltrexone,
CBI compared to no CBI increased the chance for being in the “T2: infrequent drinkers”
trajectory compared to the “T5: increasing to nearly daily” trajectory. (See Table 2 for odds
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ratios and confidence intervals for these effects.) Subjects on naltrexone who did not receive
CBI were significantly more likely than subjects on placebo and no CBI to be “T1: abstainers”
compared to “T6: nearly daily drinkers” or “T4: increasing to frequent drinkers” (OR=2.82,
95% CI: (1.34, 5.93) and OR=2.17, 95% CI: (1.21, 3.89) respectively). Subjects who received
both CBI and naltrexone compared to those who received neither were more likely to be in the
“T1: abstainer” and “T3: frequent to infrequent drinkers” trajectories than in the “T5: increasing
to nearly daily drinkers” trajectory (OR=2.81, 95% CI: (1.37, 5.74) and OR=3.52, 95% CI:
(1.55, 8.00) respectively).
In summary, CBI appears to have a unique effect on reducing the likelihood of increasing to
nearly daily drinking. Naltrexone has a unique effect on decreasing nearly daily drinking, and
the combination of naltrexone and CBI increases the chance of decreasing drinking.
3.3. Treatment adherence by trajectory of any drinking
Compliance rates by trajectory are presented in Table 3. There were significant differences in
compliance (full adherence with prescribed medication, number of CBI sessions attended for
subjects who received CBI and number of MM sessions attended) among the trajectories (p<.
0001). Compared to “T1: abstainers” all other trajectories were associated with significantly
worse medication compliance (all p<.0001). Subjects in the “T5: increasing to nearly daily
drinkers” trajectory had worse compliance than did subjects in the “T1: abstainers”, “T2:
infrequent drinkers” and “T3: frequent to infrequent drinkers” trajectories. Compared to
abstainers, all other trajectories except “T2: infrequent drinkers” were associated with
significantly fewer MM sessions attended (all p<.01). Among CBI participants, “T5: increasing
to nearly daily drinkers” or “T6: nearly daily drinkers” attended significantly fewer CBI
sessions than “T1: abstainers”, “T2: infrequent drinkers” and “T3: frequent to infrequent
drinkers” (p<.05). Additionally, “T4: increasing to frequent drinkers” had worse CBI
compliance than did “T1: abstainers” (p=.01).
3.4. Heavy drinking outcome – increasing the number of trajectories
We selected the model with four trajectories as best fitting for heavy drinking. The results were
similar to the results with three trajectories and are available upon request. The four-trajectory
model also identified trajectories of “abstainers from heavy drinking” and “consistent heavy
drinkers” but there were two rather than one trajectory in between. Subjects in the first of these
two middle trajectories had about 15% chance of heavy drinking throughout the 16 weeks.
Subjects in the second one increased their chance of drinking from 30% to about 40%.
3.5. Covariate Analyses
Both baseline percent days abstinent and percent heavy drinking days were significantly
associated with post-randomization drinking trajectories. In the three-trajectory models, higher
percent days abstinent was associated with significantly lower chance to be in the “consistent
drinkers” trajectory (OR=0.97, 95% CI = (0.96, 0.98)) than in the “abstainers” trajectory. And
higher percent heavy drinking days was associated with significantly higher chance to be in
the “consistent heavy drinkers” trajectory (OR= 1.02, 95% CI = (1.01, 1.03)) than in the
“abstainers from heavy drinking” trajectory. Similarly in the six-trajectory model for any
drinking, higher percent days abstinent was associated with significantly lower chance to be
in the “T5: increasing to nearly daily” and “T6: nearly daily drinkers” trajectories.
4. Discussion
In these re-analyses of COMBINE data, we identified six clinically useful trajectories of any
drinking, replicated a three trajectory solution for heavy drinking, showed that naltrexone and
CBI increase the probability of lower risk trajectories and established an association between
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compliance and drinking trajectories. Although the overall conclusions about the efficacy of
naltrexone, CBI and acamprosate are consistent with the conclusions drawn based on
traditional summary measures, we believe that the application of trajectory analyses to the
COMBINE study data helped provide a more complete and nuanced representation of drinking
during treatment and the aspects of drinking that the various treatments affected. For example,
in the original COMBINE analyses, the overall percentage of days abstinent was high and the
differences between treatments, while significant, small. However, the trajectory analyses
reveal several patterns of response that vary in the frequency of initial drinking and changes
in the frequency over time. The treatments also influenced membership in some but not every
trajectory of response, providing insights into how these treatments operate and suggesting that
there are subgroups of individuals who derive greater benefit from specific treatments than
observed on summary measures averaged over the entire sample. Although we replicated the
finding of three trajectories of drinking seen in the VA naltrexone study and the women’s study,
for any drinking six trajectories better reflected the data in the COMBINE Study. This could
be due to the larger sample size and the fact that there were two levels of behavioral intervention
in COMBINE, a low intensity medication management approach (MM) and a more intensive
approach combining CBI with MM, whereas the other studies all provided only a more
intensive weekly CBI. Consistent with the primary outcome paper, trajectory analysis did not
reveal significant effects of acamprosate alone or in combination with other treatments.
Of the six trajectories of any drinking, three reflected trajectories of poor or worsening
outcomes. Naltrexone and CBI influenced the probability of being in these less desirable
trajectories as is most clearly seen from Figure 6. Specifically naltrexone alone reduced the
probability of being in the “T6: nearly daily” trajectory and in the “T4: increasing to frequent
trajectory”. This finding is consistent with a potential mechanism of this treatment, in which
decreased reinforcement from alcohol could lead to reductions in drinking (Sinclair, 1990).
Naltrexone has been shown to alter responses to alcohol even after a single dose in the
laboratory (Swift et al., 1994;King et al., 1997; McCaul et al., 2001) and in clinical trials
(O’Malley et al., 1996;Volpicelli et al., 1995). It also reduces the probability of continued
drinking following an initial episode of alcohol consumption in clinical trials (Anton et al.,
1999) and in laboratory paradigms (O’Malley et al., 2003;Anton et al., 2004;Krishnan-Sarin
et al., 2007).
In contrast, CBI with or without naltrexone reduced the probability of being in the “T5:
increasing to nearly daily” trajectory while it did not decrease the probability of being in the
“T6: nearly daily drinking trajectory” (Figure 6). This finding is consistent with the potential
mechanism of a behavioral treatment in which learning new skills can prevent relapse in the
face of high-risk situations. Unlike naltrexone, which occupies brain opiate receptors after a
single dose and therefore may have immediate therapeutic effects, a single session of CBI may
be insufficient to prevent early relapse to nearly daily drinking. In CBI, training in new coping
skills does not begin until after the first four – five sessions, which focus on building motivation
for change and development of a treatment plan (Longabaugh et al. 2005). As a result,
participants who resume nearly daily drinking and potentially discontinue therapy early will
not experience the potential benefit of learning new coping skills. In contrast, individuals who
receive adequate exposure to CBI will have new tools that they can use to cope with situations
that might otherwise lead to escalation of their drinking.
This reasoning may explain why CBI does not significantly change the probability to be in the
worst trajectory when compared to placebo. However, it does not explain why the combination
of CBI and naltrexone compared to naltrexone alone appears to increase the probability of
being in the “T6: nearly daily” trajectory. One can interpret these findings in two ways. If one
chooses to focus on the “T6: nearly daily drinking” trajectory by itself, then it seems that CBI
may worsen outcome when added to naltrexone. On the other hand, one might choose to focus
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on the combination of the two worst trajectories (“T5: increasing to nearly daily” and “T6:
nearly daily” drinking) since both groups end up with the same undesirable outcome: nearly
daily drinking. In this case, looking at the combination of the two topmost bars in Figure 6 by
treatment, one can see that CBI decreases the probability of being in the two least desirable
trajectories considered together and hence is associated with good outcome overall.
The remaining three trajectories of any drinking reflect outcomes that are more positive. Both
naltrexone (alone or in combination with CBI) and CBI alone increased the probability of being
in the “T1: abstainer” trajectory and CBI increased the chance of being in the “T2: infrequent
drinkers” trajectory. The most novel trajectory identified was the “T3: frequent to infrequent”
trajectory in which the frequency of drinking declined over time. Interestingly, naltrexone plus
CBI increased the chance to be in this trajectory. One can imagine that naltrexone may have
decreased the reinforcing value of alcohol while the new cognitive and behavioral tools taught
in CBI capitalized on this effect (or vice versa). Both processes would require some time to
have their effect based on an extinction model for naltrexone and a skill acquisition model for
CBI. This finding is of note in relationship to the findings of the primary outcome analyses of
the COMBINE study (Anton et al., 2006), in which the combination of naltrexone plus CBI
did not improve outcomes across a number of drinking outcome measures over that of either
naltrexone or CBI alone. The difference between the present results and those from the primary
COMBINE outcome paper highlights the potential benefit of more refined trajectory methods
in identifying the efficacy of interventions for drinking subtypes.
As would be expected, baseline drinking was a strong predictor of trajectory membership and
was an important covariate in the analyses. For example, individuals with higher days of
abstinence pretreatment were less likely to be in the “T6: nearly daily” and “T5: increasing to
nearly daily” trajectories, levels of drinking that they did not engage in before treatment.
With regard to trajectories of heavy drinking, the analysis of the COMBINE Study replicated
the three trajectory patterns (i.e., “abstainers from heavy drinking”, “sporadic heavy drinkers”
and “consistent heavy drinkers”) found in the VA naltrexone trial. Consistent with the results
of that study, naltrexone (with or without CBI) reduced the probability of being in the consistent
heavy drinking trajectory and increased the probability of being in the abstainer trajectory. CBI
without naltrexone also reduced the probability of being in the consistent heavy drinking
trajectory and increased the probability of being in the abstainer from heavy drinking trajectory.
In contrast to the VA study, naltrexone also reduced the probability to be in the sporadic heavy
drinking trajectory, but only in the absence of CBI. It may be that this effect of naltrexone is
only evident in combination with less intensive therapy. In the VA Study, all participants
received therapy that was more intensive (i.e., weekly Twelve Step Facilitation Therapy and
medication adherence counseling).
In contrast to the analyses of any drinking, increasing the number of trajectories was less
informative for heavy drinking. For simplicity of presentation, we chose to focus on the three-
trajectory solution. Given that heavy drinking is a less frequent event than any drinking, it is
perhaps not surprising that we observed fewer trajectories. It is conceivable that additional
unique trajectories might be identified in other studies depending on participant characteristics,
the treatments studied, and other methodological issues. For example, topiramate studies have
enrolled consistent heavy drinkers who were actively drinking at the time of randomization
(Johnson et al., 2003,2007). The application of trajectory analyses to these data might identify
a trajectory of heavy drinking in which individuals move from frequent heavy drinking to
infrequent heavy drinking or abstaining from heavy drinking.
The contribution of treatment adherence to treatment response has been emphasized for
medications (Pettinati et al., 2006) and for behavioral interventions (Dearing et al., 2005). To
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begin to explore this issue, we compared measures of compliance with medication, MM
sessions and CBI sessions (for those who received CBI) for the various trajectories of any
drinking. With the exception of the number of MM sessions attended for the infrequent drinker
trajectory, adherence to each component of treatment was significantly higher in the abstainer
trajectory compared to the remaining trajectories. In most studies, those who adhere to
treatment experience better outcomes (Zweben et al., 2008; Fuller et al., 1986; Cramer et al.,
2003). Adherence to an effective treatment, however, can improve outcomes relative to
alternative treatment (e.g., placebo) (Baros et al., 2007; Volpicelli et al., 1997). In our analyses,
the two trajectories in which drinking worsened over time (i.e., infrequent to frequent and
frequent to nearly daily) were associated with the lowest treatment adherence raising the
question of whether efforts to promote adherence (e.g., long acting formulations of medications
or other behavioral interventions) might be useful in intercepting escalating use if identified
early. Based on our analyses we cannot ascertain a causal relationship between compliance
and outcome as better outcomes can lead to better compliance just as easily as better compliance
can lead to better outcomes. In future analyses, we plan to examine trajectories of adherence
to each of the COMBINE treatments and their statistical and temporal association with drinking
trajectories and thus attempt to understand the relationship between treatment adherence and
treatment outcomes.
Although trajectory analyses provided new information about treatment response, not all
questions are answered by this approach. While we can say that a treatment alters the chance
to be in a particular trajectory, the results do not tell us what happens for an individual
participant. For example, naltrexone reduced the chance to be in the nearly daily trajectory and
increased the chance to be in the abstainer trajectory. However, we cannot interpret this to
mean that a particular individual will move directly from the daily trajectory to the abstainer
trajectory or that a subject might be shifted to a better intermediate trajectory (e.g., frequent to
infrequent) while another subject shifts from frequent to infrequent into the abstainer trajectory.
Furthermore, our analysis is predicated on the assumption that different classes of trajectories
exist. When no categorically different trajectories exist, a substantial percent of subjects will
not be reliably classified into any one trajectory. Our good classification accuracy gives some
reassurance that in this study categorically different classes do exist.
Sample size and percent abstainers limit the number and shape of considered trajectories.
However, since COMBINE is the largest to date study of pharmacotherapies and behavioral
therapies for alcoholism, power to detect distinct trajectories in this study is greater than in
most other studies.
Strict inclusion/exclusion criteria in COMBINE resulted in a relatively homogeneous sample
of potentially more capable and compliant patients, who were able to achieve four days of
abstinence prior to treatment. Thus, the trajectories that we identified and the probabilities of
membership in each trajectory may not generalize to a more severe population.
In conclusion, the trajectory analyses provided new insights beyond the original findings from
the COMBINE Study, which used more traditional summary outcomes and data analytic
approaches. Distinct trajectories of response were identified that were differentially influenced
by the various interventions. As such, our analysis of the COMBINE study data highlights the
potential value of trajectory analysis as applied to clinical trials.
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Three trajectories of any drinking. Solid lines with symbols represent sample-based
probabilities of drinking based on all subjects weighted by the posterior probability of trajectory
membership. Solid lines without symbols represent model-based probabilities of drinking over
time for each trajectory group.
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Three trajectories of heavy drinking. Solid lines with symbols represent sample-based
probabilities of drinking based on all subjects weighted by the posterior probability of trajectory
membership. Solid lines without symbols represent model-based probabilities of drinking over
time for each trajectory group.
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Probabilities of trajectory membership in any drinking model with three trajectories.
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Probabilities of trajectory membership in heavy drinking model with three trajectories.
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Six trajectories of any drinking. Note: Solid lines with symbols represent sample-based
probabilities of drinking based on all subjects weighted by the posterior probability of trajectory
membership. Solid lines without symbols represent model-based probabilities of drinking over
time for each trajectory group.
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Probabilities of trajectory membership in any drinking model with six trajectories.
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Table 1
Odds ratios and 95% confidence intervals for the interaction between naltrexone and CBI on heavy drinking













































Indicates odds ratios with p < 0.05.
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Table 2
Significant odds ratios and 99% confidence intervals for the interaction between naltrexone and CBI, and for the








Trajectory Reference Trajectory Odds Ratio (95%
CI)




Abstainers Increasing to nearly
daily
2.26 (1.38, 3.70)*




Infrequent drinkers Increasing to nearly
daily
2.60 (1.55, 4.37)*




Frequent to infrequent Increasing to nearly
daily
2.96 (1.67, 5.27)*




Nearly daily drinkers Increasing to nearly
daily
2.69 (1.16, 6.24)*
CBI vs. no CBI No naltrexone Infrequent drinkers Increasing to nearly
daily
2.79 (1.38, 5.65)*
CBI vs. no CBI Naltrexone Increasing to frequent Increasing to nearly
daily
3.12 (1.32, 7.38)*
CBI vs. no CBI Naltrexone Frequent to infrequent Increasing to frequent 3.49 (1.52, 7.99)*





No CBI Abstainers Nearly daily drinkers 2.82 (1.34, 5.93)*
Naltrexone vs.
no naltrexone














Indicates odds ratios with p < 0.01.
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